The mechanisms behind protein PEGylation are complex and dictated by the structure of the protein reactant. Hence, it is difficult to design a reaction process which can produce the desired PEGylated form at high yield. Likewise, efficient purification processes following protein PEGylation must be constructed on an ad hoc basis for each product. The retention and binding mechanisms driving ele...

Cysteine PEGylation includes several steps, and is difficult to manage in practice. In the current investigation, the cysteine PEGylation of erythropoietin analogs was examined using computational and nonglycosylated systems to define a simpler approach for specific PEGylation. Two model analogs (E31C and E89C) were selected for PEGylation based on lowest structural deviation from the native fo...

As one of fibroblast growth factor (FGF) family members, FGF21 has been extensively investigated for its potential as a drug candidate to combat metabolic diseases. In the present study, recombinant human FGF21 (rhFGF21) was modified with polyethylene glycol (PEGylation) in order to increase its in vivo biostabilities and therapeutic potency. At N-terminal residue rhFGF21 was site-selectively P...

Purpose: The goal of this work was to develop a fast and accurate method to monitor PEGylation reactions by using HPLC with complementary UV/Vis and charged aerosol detection. It is an increasingly common practice to modify biotherapeutic peptides, proteins and small molecules by attaching chemical groups designed to enhance properties such as bioavailability, potency or stability. One example ...

Cholesterol–PEG–Cholesterol could be a new alternative for PEGylation of liposomes.

objective:at the present study, relationship between phagocytosis of plga particles and combined effects of particle size and surface pegylation was investigated.  materials and methods:microspheres and nanospheres (3500 nm and 700 nm) were prepared from three types of plga polymers (non-pegylated and pegylation percents of 9% and 15%). these particles were prepared by solvent evaporation metho...

Background: DAB389IL-2 is considered a fusion immunotoxin and it is used for the CTCL therapy. DAB389IL-2 includes of two distinct portions; the catalytic domain of diphtheria toxin and IL-2. DAB389IL-2 duo to the presence of a free cysteine residue (Cys 513 in IL-2 part) is prone to unwanted intramolecular and intermolecular disulfide bonds formation and aggregation problems. Aggregation is co...